OUR TEAM: Greg Meline


Jamin.jpg

Greg Meline
Senior Director
greg.meline@scimitar-inc.com

Greg brings over thirteen years of experience leading operational transformations at life science companies. His clients range from top global pharma to biotech firms in the US, Europe, and Japan. Greg has pioneered successful engagements in the areas of post-merger integration, strategic sourcing, pharmacovigilance, and supply-chain management.

Before joining Scimitar, Greg served as a Director at PwC. Prior to PwC’s acquisition or PRTM, Greg served as a Principal at PRTM Management Consultants.

Greg earned his MBA from the International University of Japan and is fluent in Japanese and English. Greg is also Certified in Production and Inventory Management (CPIM) by APICS.


Project Experience

  • Most recently, Greg led an effort for a Site Services organization to assess and develop a new workforce model to ensure they have the right capabilities to efficiently and effectively meet business and customer needs 3-5 years out
  • Greg led the program management office in the design and implementation of a new global procurement organization for a top-5 biopharmaceutical firm, targeting over $1B in savings across all categories of spend
  • Led the successful transition and post-close integration of a CMO facility to a top-10 biopharmaceutical firm, managing the organization and coordination of 12 client teams, involving over 120 contributors
  • Served as a project leader on a key integration team for the merger of one of the leading global pharma companies with its Japanese affiliate
  • Designed and developed a comprehensive solution and implementation plan for an entirely new global pharmacovigilance organization of a top-5 pharma
  • Led the successful analysis, development, and execution of a strategic sourcing solution for drug safety, generating an estimated $25 million in savings over 5 years for a top-5 pharma
  • Most recently, Greg led the program management office in the design and implementation of a new global procurement organization for a top-5 biopharmaceutical firm, targeting over $1B in savings across all categories of spend